PHOTOFRIN
Details
- Status
- Prescription
- First Approved
- 1995-12-27
- Routes
- Injection, INJECTION
- Dosage Forms
- Injectable, INJECTABLE
PHOTOFRIN Approval History
What PHOTOFRIN Treats
3 indicationsPHOTOFRIN is approved for 3 conditions since its original approval in 1995. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Esophageal Cancer
- Non-Small Cell Lung Cancer
- Barrett's Esophagus
Drugs Similar to PHOTOFRIN
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PHOTOFRIN FDA Label Details
ProIndications & Usage
FDA Label (PDF)PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.